Core Viewpoint - The new stablecoin regulations in Hong Kong have officially come into effect, requiring issuers to obtain a license from the Financial Management Commissioner for any fiat-backed stablecoin issuance [1] Group 1: Regulatory Framework - The Hong Kong Monetary Authority (HKMA) has released multiple documents outlining requirements for stablecoin issuers, including financial conditions, qualifications, and reserve assets [3] - The documents specify that applicants for stablecoin licenses must be registered corporations in Hong Kong with a minimum paid-up capital of 25 million HKD [3] - Reserve assets for licensed stablecoin issuers must be of high quality and liquidity, with minimal investment risk, and must be able to meet redemption requests within one business day [3] Group 2: Reserve Asset Requirements - The reserve asset composition must have a market value equal to or greater than the total face value of the stablecoins in circulation [3] - Licensed issuers are required to over-collateralize their reserve assets to manage market volatility and must appoint qualified custodians for asset management [3] Group 3: Currency Pegging and Custodianship - Issuers can choose to peg their stablecoins to a single fiat currency or a basket of currencies, with the option to apply for additional pegged currencies [4] - Potential issuers have indicated interest in pegging to freely convertible currencies such as the Hong Kong Dollar and the US Dollar [5] - Licensed institutions are encouraged to use Hong Kong licensed banks as custodians for reserve assets, although offshore banks can be used if they meet equivalent asset protection standards [5] Group 4: Market Sentiment and Caution - The HKMA has cautioned about the risks of concept bubble formation in the stablecoin market, urging the public to remain cautious of overly exuberant market sentiments [6] - Initial licensing will be limited, and even licensed companies may face uncertainties regarding short-term profitability [6] - The HKMA emphasizes the need for a cooling effect on the market, as discussed by its president in a recent article [6]

Core Insights - Visa is expanding its settlement platform to support two additional USD stablecoins: Global Dollar (USDG) and PayPal Dollar (PYUSD), as well as two blockchain networks, Stellar and Avalanche, and a Euro-backed stablecoin, EURC [1] Group 1 - Visa's global growth products and strategic partnerships head, Rubail Birwadker, stated that the company is building a multi-currency and multi-chain infrastructure to meet the needs of global partners [1] - The company believes that when stablecoins are trusted, scalable, and interoperable, they can fundamentally change the way currency flows globally [1]

【文/观察者网 陶立烽】 今天（8月1日），全球第一个针对法币稳定币的全面监管框架——香港《稳定币条例》正式实施，相关 机构可以开始申请牌照。 就在不久前，美国总统特朗普也签署了三个加密货币法案。相比于美国，香港的稳定币法案更加简洁明 了，也更加严厉：2500万港元准入门槛、100%资产抵押、1日内赎回保障。 一位从事10年稳定币相关业务的行业人士邵星认为，未来稳定币发行后，需要寻找渠道和流量平台来承 接，要有大量的应用场景来落地。邵星也预计，之后五年左右，以合规稳定币为基础的点对点支付方式 逐渐代替SWIFT（国际资金清算系统），整个金融体系会发生重大变化。 稳定币是什么？ 到今年6月下旬，加密资产的总市值已经超过3万亿美元，超过法国去年GDP，其中稳定币的规模达到 2600亿美元左右，较2020年增长超40倍。 稳定币自2014年诞生，最初并未受到广泛关注。当时加密货币市场尚处于早期阶段，用户仍可用传统货 币直接买卖加密资产，稳定币作为中间介质的需求有限。随着越来越多国家对法币与加密货币之间的兑 换实施限制或禁令，稳定币逐渐成为加密资产市场内部交易的重要媒介，并在全球范围内流行起来。 而这一轮的热潮开始于 ...

Core Viewpoint - Huajian Medical has transformed from an IVD distributor to a "medical innovation drug chain investment bank" within 18 days, driven by a series of strategic actions and market enthusiasm, resulting in a significant increase in market capitalization from 3.6 billion to nearly 8 billion HKD [1][7]. Group 1: Strategic Actions - On July 14, Huajian Medical announced its plan for a dual primary listing on NASDAQ to expand its international shareholder base [4]. - Three days later, the company introduced the world's first medical innovation drug RWA exchange, IVDNewCo Exchange, along with a supporting stablecoin, IVDDollar (IVDD) [4]. - The establishment of a wholly-owned subsidiary, IVD GROUP INC., in New York was completed on July 20, with applications for stablecoin licenses submitted to the SEC and CFTC [4]. - From July 23 to 28, the company executed three high-priced buybacks, spending over 6.13 million HKD to repurchase 1.721 million shares, with average transaction prices rising from 3.16 HKD to 3.67 HKD [4]. - On July 29, the subsidiary Weida secured a multi-million HKD revolving loan led by East Asia Bank, showcasing financial institutions' endorsement of the company's development [4]. - A brand strategy upgrade was announced on July 30, with a new logo and a redefined brand essence of "Innovation-Verification-Development" [4]. - The same day, a partnership was formed with BGI's CoWin to establish an innovative drug intellectual property tokenization fund, facilitating the last mile of medical asset blockchain integration [4]. Group 2: Market Dynamics - The innovative drug industry is experiencing a value reassessment, with 48 out of 93 new drugs approved by the drug regulatory agency in 2024 being innovative drugs, and the scale of outbound licensing transactions soaring to 51.9 billion USD [8]. - As of July 29, the China Securities Hong Kong Stock Connect Innovative Drug Index has risen over 124% from its low point at the beginning of the year, with 16 innovative drug funds doubling their returns [8]. - The global regulatory landscape for stablecoins is evolving, with the U.S. "Genius Act" and Hong Kong's stablecoin regulations coming into effect, establishing a compliance network across Europe, the U.S., and Asia [8]. Group 3: Valuation Revolution - Following the announcement of the dual listing on July 14, Huajian Medical's stock price began a rapid ascent, with a cumulative increase of 75.1% from July 14 to 21 [9]. - On July 31, the stock price peaked at 4.99 HKD, marking a 15.78% increase for the day, and pushing the market capitalization to 8 billion HKD [9]. - The company's valuation is shifting from a traditional IVD distributor's sales multiple to an ecological premium associated with the medical RWA exchange [9]. Group 4: Future Outlook - Huajian Medical aims to become a leader in the medical RWA sector, akin to NASDAQ for medical asset tokenization, Visa for stablecoin payment scenarios, and Apple for integrating technology, assets, and capital into a closed loop [12]. - The global RWA market is projected to reach 16.1 trillion USD by 2030, with stablecoin transaction volumes expected to surpass Visa in 2024 [10]. - The company's strategy involves creating a closed-loop ecosystem that captures innovative drug pipelines, facilitates RWA tokenization, and enables payment settlements through IVDD stablecoin [10].

Core Viewpoint - The rapid transformation of Huajian Medical into a "new species" in the capital market is driven by its strategic actions, including a dual primary listing in the U.S. and the launch of innovative financial products, resulting in a significant increase in market capitalization from 3.6 billion to nearly 8 billion HKD within a month [1][4][9]. Group 1: Strategic Actions - On July 14, Huajian Medical announced its plan for a dual primary listing on NASDAQ to expand its international shareholder base [4]. - Three days later, the company introduced the world's first medical innovation drug RWA exchange, IVDNewCo Exchange, along with a stablecoin, IVDDollar [5]. - The establishment of a wholly-owned subsidiary, IVD GROUP INC., in New York was announced on July 20, alongside applications for stablecoin licenses to the SEC and CFTC [5]. - From July 23 to 28, the company executed three high-priced share buybacks, spending over 6.13 million HKD to repurchase 1.721 million shares, with average transaction prices rising from 3.16 HKD to 3.67 HKD [5]. - On July 29, the subsidiary Weishida secured a multi-hundred million HKD revolving loan led by East Asia Bank, indicating strong backing from financial institutions [5]. - A brand strategy upgrade was announced on July 30, featuring a new logo symbolizing "innovation-validation-development" [5]. - The same day, a partnership with BGI Group was established to create an innovative drug intellectual property tokenization fund, enhancing the integration of medical assets on the blockchain [5]. Group 2: Market Dynamics - The innovative drug industry is experiencing a value reassessment, with 48 out of 93 new drugs approved by the drug regulatory agency in 2024 being innovative drugs, and the scale of outbound licensing transactions soaring to 51.9 billion USD [10]. - As of July 29, the China Securities Hong Kong Stock Connect Innovative Drug Index has risen over 124% from its low point at the beginning of the year, with 16 innovative drug funds doubling their returns [10]. - The global regulatory landscape for stablecoins is evolving, with the U.S. "Genius Act" and Hong Kong's stablecoin regulations coming into effect, establishing a compliance network across Europe, the U.S., and Asia [10]. Group 3: Valuation Revolution - Following the dual listing announcement on July 14, Huajian Medical's stock price surged, with a cumulative increase of 75.1% from July 14 to 21, and a peak price of 4.99 HKD per share on July 31, pushing its market capitalization to 8 billion HKD [11]. - The company's valuation is shifting from traditional IVD distribution metrics to a premium associated with its new role as a medical RWA exchange [11]. Group 4: Future Outlook - The global RWA market is projected to reach 16.1 trillion USD by 2030, with stablecoin transaction volumes expected to surpass Visa's by 2024 [12]. - Huajian Medical aims to create a closed-loop ecosystem, capturing innovative drug pipelines, tokenizing RWA, and facilitating payments through its stablecoin [12]. - The company aspires to become a leader in the medical RWA sector, akin to NASDAQ for asset tokenization, Visa for stablecoin payments, and Apple for integrating technology and capital [14].

21世纪经济报道记者 黄子潇 深圳报道 8月1日，21世纪经济报道记者获悉，香港《稳定币条例》今日正式生效。 截至记者发稿时，香港金管局尚未发出任何牌照。发牌时点晚于预期。 设6个月过渡安排及临时牌照 此前7月29日，香港金管局发布一系列咨询文件，并召开一场技术简报会。香港金管局副总裁陈维民在会上透露，将于2026年初发出首阶段牌照，首次发行 的牌照数量将为个位数。 此前，香港金管局多次强调"高门槛""首批仅数个牌照""预先沟通"的态度，被市场广泛解读为"邀请制"。7月31日，香港金管局人士对21世纪经济报道记者 表示，"邀请制"并非官方说法。 香港金管局称"邀请制"非官方说法 7月31日，香港金管局人士对21世纪经济报道记者表示，"邀请制"并非官方说法，更多为一种市场解读。 该人士表示，"邀请制（by invitation）"并未完整反映金管局的发牌模式，因为事实上有意愿、有兴趣申请的机构，均可事先主动与香港金管局沟通发牌事 宜。 一周前，香港金管局总裁余伟文透露，尽管已明确初阶段只会批出数个稳定币牌照，但至今已经有数十家机构主动接触金管局团队。 香港金管局7月29日公告也显示，鼓励有意申请牌照的机构于20 ...

21世纪经济报道记者 黄子潇 深圳报道 8月1日，21世纪经济报道记者获悉，香港《稳定币条例》今日正式生效。 截至记者发稿时，香港金管局尚未发出任何牌照。发牌时点晚于预期。 此前7月29日，香港金管局发布一系列咨询文件，并召开一场技术简报会。香港金管局副总裁陈维民在 会上透露，将于2026年初发出首阶段牌照，首次发行的牌照数量将为个位数。 此前，香港金管局多次强调"高门槛""首批仅数个牌照""预先沟通"的态度，被市场广泛解读为"邀请 制"。7月31日，香港金管局人士对21世纪经济报道记者表示，"邀请制"并非官方说法。 香港金管局称"邀请制"非官方说法 7月31日，香港金管局人士对21世纪经济报道记者表示，"邀请制"并非官方说法，更多为一种市场解 读。 该人士表示，"邀请制（by invitation）"并未完整反映金管局的发牌模式，因为事实上有意愿、有兴趣申 请的机构，均可事先主动与香港金管局沟通发牌事宜。 此外该局强调，不会公布向其表达意愿或提交申请的机构名单。 设6个月过渡安排及临时牌照 如何将现有稳定币发行业务平稳转为"合规"发行，是《稳定币条例》需要解决的问题。 此前，许多机构已实质性在香港设有法币稳 ...

8月1日，21世纪经济报道记者获悉，香港《稳定币条例》今日正式生效。截至记者发稿时，香港金管局 尚未发出任何牌照。发牌时点晚于预期。此前7月29日，香港金管局发布一系列咨询文件，并召开一场 技术简报会。香港金管局副总裁陈维民在会上透露，将于2026年初发出首阶段牌照，首次发行的牌照数 量将为个位数。此前，香港金管局多次强调"高门槛""首批仅数个牌照""预先沟通"的态度，被市场广泛 解读为"邀请制"。7月31日，香港金管局人士对记者表示，"邀请制"并非官方说法。(21世纪经济报道) ...

开源证券指出，市场交易量持续走高，中报预告超预期，稳定币带来催化，看好低估值龙头券商机会。 自营与两融业务表现稳健，财富管理转型具备差异化与长期潜力。基于行业轮动模型，8月行业组合中 非银金融板块入选，显示其短期配置价值。临近前期高点，建议关注非银、金融科技等领域的走势。当 前阶段，稳定型红利（含非银金融）在大变局下不确定性中枢上升的环境中仍具配置价值。 东方财富证券指出，券商行情主要得益于经济与政策驱动，历史超额收益多由流动性改善、政策发力和 经济企稳预期共振触发。当前中央政治局会议积极定调，强调财政与货币政策协同发力，经济企稳预期 逐步形成，叠加流动性充裕，构成券商板块配置窗口期。金融创新如虚拟资产业务有望显著增强券商盈 利能力，2030年稳定币相关收入或提升行业营收25%-72%，类比2014年创新业务对行业的拉动。基本面 方面，交投活跃、投融资改善及盈利结构优化共同推动盈利中枢上移。保险板块亦受益于利率企稳和预 定利率下调，利差损压力缓解。整体来看，非银金融行业在政策、创新及业绩多重利好下具备配置价 值。 （本文机构观点来自持牌证券机构，不构成任何投资建议，亦不代表平台观点，请投资人独立判断和决 策。 ...

Group 1: Fund Performance and Market Trends - 12 public funds have achieved a net value growth rate exceeding 100% year-to-date, primarily focusing on innovative pharmaceuticals and healthcare sectors, closely linked to the strong performance of the Hong Kong innovative drug sector [1] - The top-performing fund, Huatai-PineBridge Hong Kong Advantage Selection A, recorded a 143.24% year-to-date net value growth rate, heavily invested in Hong Kong innovative drug stocks [1] - In the A-share market, 341 companies have announced mid-term cash dividend plans, with 24 companies declaring a total cash dividend of 14.55 billion yuan, including six companies with dividends exceeding 1 billion yuan [1] Group 2: Insurance and Investment Funds - The establishment of the Tai Ping Zhi Yuan No. 1 private securities investment fund marks the increase of insurance-related private securities investment funds to six, managed by three insurance-related private fund companies [1] - These funds are primarily focused on long-term investments in secondary market stocks, indicating a significant inflow of long-term capital into the capital market [1] Group 3: Corporate Financial Performance - Apple reported a third-quarter net profit of $23.43 billion, a 9% year-on-year increase, with total revenue of $94.04 billion, up 9.6% year-on-year [2] - Amazon's second-quarter net profit reached $18.16 billion, a 34.7% year-on-year increase, with total revenue of $167.7 billion, up 13% year-on-year [3] - Microsoft achieved a fourth-quarter net profit of $27.2 billion, a 24% year-on-year increase, with total revenue of $76.44 billion, up 18% year-on-year [4] Group 4: Market Reactions and Economic Indicators - The U.S. stock market saw all three major indices decline, with the Dow Jones down 0.74%, the Nasdaq down 0.03%, and the S&P 500 down 0.37%, amid rising inflation concerns and upcoming economic data releases [8] - The technology sector experienced volatility, with significant fluctuations in the market capitalization of major tech companies, including a brief surge in Microsoft's valuation above $4 trillion [9]